Loading...

Cannabis Science

BST:CXN
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CXN
BST
$117M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid-based pharmaceutical products primarily in the United States. The last earnings update was 331 days ago. More info.


Add to Portfolio Compare Print Invest
CXN Share Price and Events
Price Volatility
Industry
5yr Volatility vs Market

CXN Value

 Is Cannabis Science undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Cannabis Science is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cannabis Science has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cannabis Science. This is due to cash flow or dividend data being unavailable. The share price is €0.04.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cannabis Science's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cannabis Science's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:CXN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2017-09-30) in USD Not available
OTCPK:CBIS Share Price ** OTCPK (2018-07-20) in USD $0.04
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 17.81x
Germany Market PE Ratio Median Figure of 407 Publicly-Listed Companies 18.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cannabis Science.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PE ratio to the industry average as no data exists.
  • Unable to calculate PE ratio for Cannabis Science, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Cannabis Science's expected growth come at a high price?
Raw Data
BST:CXN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Germany Pharmaceuticals Industry PEG Ratio Median Figure of 5 Publicly-Listed Pharmaceuticals Companies 1.45x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.37x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cannabis Science, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cannabis Science's assets?
Raw Data
BST:CXN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2017-09-30) in USD Not available
OTCPK:CBIS Share Price * OTCPK (2018-07-20) in USD $0.04
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 2.53x
Germany Market PB Ratio Median Figure of 547 Publicly-Listed Companies 1.86x

* Primary Listing of Cannabis Science.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PB ratio to the industry average as no data exists.

Next steps:

  1. Take a look at our analysis of CXN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Cannabis Science's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Pharmaceuticals industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Cannabis Science's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Cannabis Science has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CXN Future Performance

 How is Cannabis Science expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannabis Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.3%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cannabis Science expected to grow at an attractive rate?
  • Unable to compare Cannabis Science's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Cannabis Science's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Cannabis Science's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:CXN Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 13.3%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.7%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:CXN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:CXN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2017-09-30 0 -2 -8
2017-06-30 0 -2 -12
2017-03-31 0 -1 -11
2016-12-31 0 -2 -10
2016-09-30 0 -1 -16
2016-06-30 0 -1 -13
2016-03-31 0 -1 -18
2015-12-31 0 -1 -19
2015-09-30 0 -1 -23
2015-06-30 0 -1 -20
2015-03-31 0 -1 -15
2014-12-31 0 -0 -17

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Cannabis Science is high growth as no earnings estimate data is available.
  • Unable to determine if Cannabis Science is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:CXN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Cannabis Science Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:CXN Past Financials Data
Date (Data in USD Millions) EPS *
2017-09-30 -0.00
2017-06-30 -0.01
2017-03-31 -0.00
2016-12-31 -0.01
2016-09-30 -0.01
2016-06-30 -0.01
2016-03-31 -0.01
2015-12-31 -0.01
2015-09-30 -0.02
2015-06-30 -0.02
2015-03-31 -0.02
2014-12-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cannabis Science will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of CXN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Cannabis Science's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Cannabis Science's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Cannabis Science's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cannabis Science has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CXN Past Performance

  How has Cannabis Science performed over the past 5 years?

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Cannabis Science has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data. You can see them here.

Show me the analysis anyway

  • Cannabis Science's last earnings update was 331 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cannabis Science's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient past earnings data to establish if Cannabis Science's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Cannabis Science's 1-year growth to the 5-year average as past earnings data has not been reported.
  • Unable to compare Cannabis Science's 1-year growth to the DE Pharmaceuticals industry average as past earnings data has not been reported.
Earnings and Revenue History
Cannabis Science's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cannabis Science Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:CXN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2017-09-30 0.01 -8.36 9.16 0.55
2017-06-30 0.01 -11.81 8.73 0.43
2017-03-31 0.01 -10.86 8.30 0.36
2016-12-31 0.01 -10.12 7.29 0.31
2016-09-30 0.05 -16.45 9.57 0.68
2016-06-30 0.05 -13.22 10.20 0.75
2016-03-31 0.05 -17.57 13.37 0.77
2015-12-31 0.04 -18.62 12.57 0.80
2015-09-30 0.00 -22.94 14.54 0.51
2015-06-30 0.00 -19.90 12.18 0.45
2015-03-31 0.00 -15.40 8.72 0.33
2014-12-31 0.00 -16.88 10.12 0.14
2014-09-30 0.01 -10.11 6.34 0.01
2014-06-30 0.08 -10.62 6.25
2014-03-31 0.08 -9.98 5.62
2013-12-31 0.08 -5.93 3.33
2013-09-30 0.08 -5.83 4.04
2013-06-30 -0.09 -6.78 3.97
2013-03-31 -0.08 -10.35 4.61
2012-12-31 0.04 -16.04 5.33
2012-09-30 0.03 -16.49 3.65
2012-06-30 0.12 -15.75 3.67
2012-03-31 0.18 -13.02 3.37
2011-12-31 0.07 -8.34 3.17

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Unable to establish if Cannabis Science has efficiently used shareholders’ funds last year as no Return on Equity data is available.
  • Unable to establish if Cannabis Science has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as past financial data has not been reported.
  • Unable to establish if Cannabis Science improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.

Next steps:

  1. When a company lacks a financial track record, its management’s track record becomes important. Corporate governance also plays an important role in a young business as board members are seen as highly-experienced leaders to help steer the company into the future. Take a look at Cannabis Science's management and board experience and expertise to assess their ability to deliver on their strategic promises.
  2. Past financial records are usually unavailable for companies that have just been established or recently publicly listed, which makes them inherently riskier. Take a look at a list of well-established companies here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Past performance checks
We assess Cannabis Science's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cannabis Science has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CXN Health

 How is Cannabis Science's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cannabis Science's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Unable to compare short term assets to short term liabilities as Cannabis Science has not reported sufficient balance sheet data.
  • Unable to establish if Cannabis Science's long term commitments exceed its cash and other short term assets as Cannabis Science has not reported sufficient balance sheet data.
Balance sheet
This treemap shows a more detailed breakdown of Cannabis Science's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Unable to establish if Cannabis Science has a high level of physical assets or inventory without balance sheet data.
  • Unable to verify if debt is covered by short term assets as Cannabis Science has not reported sufficient balance sheet data.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cannabis Science Company Filings, last reported 1 year ago.

BST:CXN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2017-09-30 -3.16 2.73 0.03
2017-06-30 -2.54 2.77 0.32
2017-03-31 -2.43 2.41 0.32
2016-12-31 -1.79 2.08 0.33
2016-09-30 -4.34 2.41 0.01
2016-06-30 -3.13 1.67 0.03
2016-03-31 -2.68 1.67 0.02
2015-12-31 -2.61 1.74 0.06
2015-09-30 -3.61 1.73 0.00
2015-06-30 -2.85 1.78 0.00
2015-03-31 -2.45 1.66 0.04
2014-12-31 -2.57 1.77 0.01
2014-09-30 -3.16 2.03 0.63
2014-06-30 -2.92 2.28 1.00
2014-03-31 -2.46 2.28 1.41
2013-12-31 -3.52 2.29 0.23
2013-09-30 -2.97 1.78 0.20
2013-06-30 -2.71 1.48 0.32
2013-03-31 -2.16 1.41 0.65
2012-12-31 -2.17 1.50 0.55
2012-09-30 -1.55 1.05 0.01
2012-06-30 -1.14 0.68 0.00
2012-03-31 -2.21 0.27 0.00
2011-12-31 -2.23 0.19 0.00
  • Unable to establish if Cannabis Science's level of debt is high without past debt data.
  • Unable to establish if Cannabis Science's debt level has increased without past 5-year debt data.
  • Unable to verify if debt is well covered by operating cash flow as Cannabis Science has not reported sufficient balance sheet data.
  • Unable to confirm if the interest payments on Cannabis Science's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Cannabis Science's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cannabis Science has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CXN Dividends

 What is Cannabis Science's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cannabis Science dividends.
If you bought €2,000 of Cannabis Science shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cannabis Science's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cannabis Science's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:CXN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 31 Stocks 3.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 322 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cannabis Science has not reported any payouts.
  • Unable to verify if Cannabis Science's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cannabis Science's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cannabis Science has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cannabis Science's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cannabis Science afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cannabis Science has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CXN Management

 What is the CEO of Cannabis Science's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Raymond Dabney, image provided by Google.
Raymond Dabney
COMPENSATION $418,842
AGE 53
TENURE AS CEO 3.9 years
CEO Bio

Mr. Raymond C. Dabney is a Co-Founder of Crown Baus Capital Corp. and has been its Chief Executive Officer and President since January 13, 2015. Mr. Dabney is a Co-founder of Cannabis Science, Inc. and has been its President and Chief Executive Officer since November 5, 2014. He served as the Managing Consultant of Crown Baus Capital Corp. until March 2014 until January 2015. He served as Management Consultant at Cannabis Science, Inc. He served as the President and Chief Executive Officer of T.W. Christian, Inc. (formerly, XRAYMEDIA.com Inc.) from October 25, 1999 to November 2005 and served as its Secretary & Treasurer. He served as the Chief Financial Officer of T.W. Christian, Inc. (formerly, XRAYMEDIA.com Inc.). Since 1990, Mr. Dabney served as President and Chief Executive Officer of Command Communications, Inc. of Vancouver, British Columbia. From 1991 To 1993, Mr. Dabney acted as Western Regional General Manager of Unitel Communications of Vancouver, British Columbia and From 1989 To 1991 Mr. Dabney served as an inside Sales Manager for Morgan Whitney trading Group Ofvenice Beach, California. Mr. Dabney served as an Executive Officer of Cannabis Science, Inc. Mr. Dabney serves as Chairman of the Board of Cannabis Science, Inc. and has been its Director since November 5, 2014. He has been a Director of Crown Baus Capital Corp. since January 13, 2015. He served as a Director of T.W. Christian, Inc. since October 25, 1999.

CEO Compensation
  • No earnings data for Cannabis Science, not possible to compare to compensation.
  • Raymond's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Cannabis Science management team in years:

3.5
Average Tenure
56
Average Age
  • The tenure for the Cannabis Science management team is about average.
Management Team

Raymond Dabney

TITLE
Co-Founder
COMPENSATION
$419K
AGE
53
TENURE
3.9 yrs

Benjamin C. Tam

TITLE
Chief Financial Officer
COMPENSATION
$113K
AGE
66
TENURE
2.1 yrs

Robert Kane

TITLE
Chief Operating Officer
COMPENSATION
$260K
AGE
42
TENURE
2.1 yrs

Mario Lap

TITLE
President of European Operations & Director
COMPENSATION
$215K
AGE
66

Bret Bogue

TITLE
Director of Horticulture and Head of Research & Development

Christopher Meenan

TITLE
Executive Vice President of Product Research & Development
TENURE
5.9 yrs

Alfredo Dupetit-Bernardi

TITLE
Chief Executive Officer and President of Cannabis Science GmbH
AGE
56
TENURE
3.1 yrs

Andrew Pitsicalis

TITLE
International Brand & Licensing Director
TENURE
6.5 yrs

Christopher Stubbs

TITLE
Lab Director
Board of Directors Tenure

Average tenure and age of the Cannabis Science board of directors in years:

4.3
Average Tenure
66
Average Age
  • The tenure for the Cannabis Science board of directors is about average.
Board of Directors

Benjamin C. Tam

TITLE
Chief Financial Officer
COMPENSATION
$113K
AGE
66
TENURE
2.1 yrs

Robert Kane

TITLE
Chief Operating Officer
COMPENSATION
$260K
AGE
42
TENURE
4.9 yrs

Mario Lap

TITLE
President of European Operations & Director
COMPENSATION
$215K
AGE
66
TENURE
5.8 yrs

Julius Garvey

TITLE
President of Scientific Advisory Board
TENURE
0.1 yrs

Raymond Dabney

TITLE
Co-Founder
COMPENSATION
$419K
AGE
53

Jacques Walker

TITLE
President of International Government Affairs Advisory Board
TENURE
0.1 yrs

Bob Melamede

TITLE
Member of Scientific Advisor Board
COMPENSATION
$386K
AGE
70
TENURE
4.3 yrs

Ritchard Fishman

TITLE
Member of Scientific Advisory Board
TENURE
9.2 yrs

Roscoe Moore

TITLE
Member of Scientific Advisory Board & Member of International Government Affairs Board
COMPENSATION
$260K
AGE
64

J. August

TITLE
Member of Scientific Advisory Board
AGE
90
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Start End Shares Value (USD)
13. Jan 18 Sell Benjamin C. Tam Individual 11. Jan 18 12. Jan 18 -193,626 $-19,368.97
09. Jan 18 Sell Robert Kane Individual 04. Jan 18 04. Jan 18 -400,000 $-37,480.00
04. Jan 18 Sell Robert Kane Individual 03. Jan 18 03. Jan 18 -200,000 $-25,250.00
29. Dec 17 Sell Robert Kane Individual 27. Dec 17 29. Dec 17 -200,000 $-20,870.00
27. Dec 17 Sell Robert Kane Individual 19. Dec 17 19. Dec 17 -100,000 $-5,000.00
04. Dec 17 Sell Robert Kane Individual 30. Nov 17 30. Nov 17 -198,820 $-10,994.75
X
Management checks
We assess Cannabis Science's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cannabis Science has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CXN News

External News
Loading...
Simply Wall St News

CXN Company Info

Map
Description

Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid-based pharmaceutical products primarily in the United States. The company is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. Its drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions. In addition, the company offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, benefits of medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug; and a research collaboration agreement with Dana-Farber Cancer Institute, Inc. to develop and investigate the use of cannabinoids to cure various cancers, as well as with Stellenbosch University to treat chronic pelvic pain associated with pelvic inflammatory disease in women, chronic prostatitis in men, and other chronic pain associated with other indications. The company was formerly known as Gulf Onshore, Inc. and changed its name to Cannabis Science, Inc. in April 2009. The company was incorporated in 1996 and is based in Irvine, California. Cannabis Science, Inc. is a subsidiary of Weedmaps Media, Inc.

Details
Name: Cannabis Science, Inc.
CXN
Exchange: BST
Founded: 1996
$101,178,844
2,746,005,296
Website: http://www.cannabisscience.com
Address: Cannabis Science, Inc.
19800 MacArthur Boulevard,
Suite 300,
Irvine,
California, 92612,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK CBIS Common Stock Pink Sheets LLC US USD 31. Mar 2009
BST CXN Common Stock Boerse-Stuttgart DE EUR 31. Mar 2009
Number of employees
Current staff
Staff numbers
0
Cannabis Science employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/10/17 13:31
End of day share price update: 2018/07/20 00:00
Last earnings filing: 2017/11/20
Last earnings reported: 2017/09/30
Last annual earnings reported: 2016/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.